| |
Reference
|
HR (95% CI)
|
|---|
|
Variable
|
ABT (n = 390)
|
ADA (n = 374)
|
CZP (n = 135)
|
ETN (n = 616)
|
GLM (n = 208)
|
IFX (n = 650)
|
TCZ (n = 364)
|
P value
|
|---|
|
Lack of effectiveness
|
1
|
1.4 (1.0–2.1)
|
2.4 (1.5–3.8)***
|
1.7 (1.2–2.4)**
|
1.1 (0.7–1.7)
|
1.5 (1.1–2.2)*
|
1.1 (0.8–1.7)
|
< 0.001
|
|
All toxic adverse events
|
1
|
2.8 (1.5–5.2)***
|
1.7 (0.7–4.0)
|
4.0 (2.3–6.9)***
|
2.5 (1.3–4.8)**
|
4.3 (2.5–7.3)***
|
2.2 (1.2–4.2)*
|
< 0.001
|
|
Non-toxic reasons
|
1
|
0.8 (0.5–1.3)
|
0.3 (0.1–0.9)*
|
1.1 (0.7–1.6)
|
1.5 (0.9–2.5)
|
1.0 (0.7–1.5)
|
1.1 (0.7–1.8)
|
0.07
|
|
Remission
|
1
|
2.9 (1.5–5.4)***
|
1.8 (0.8–4.4)
|
1.0 (0.5–2.0)
|
2.4 (1.2–5.0)*
|
3.1 (1.7–5.6)***
|
2.5 (1.3–4.8) **
|
< 0.001
|
|
All adverse events (including lack of effectiveness and toxic adverse events)
|
1
|
1.8 (1.3–2.5)***
|
2.5 (1.6–3.7) ***
|
2.3 (1.7–3.1)***
|
1.5 (1.0–2.2)*
|
2.1 (1.6–2.9)***
|
1.4 (1.0–2.0)*
|
< 0.001
|
- bDMARDs biological disease-modifying antirheumatic drugs, PSL prednisolone, MTX methotrexate, HR hazard ratio, 95% CI 95% confidence interval, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab
- *P < 0.05, **P < 0.01, ***P < 0.001
